BOL: Related items

SOWDHAMINI Lab

Sun, 15 Sep 2013 09:19:12 -0500

Genome sequencing projects have enormous potential for benefiting human endeavors. However, just as acquiring a language's vocabulary does not enable one to speak it, databases that list the amino acid composition of proteins do not directly tell us much about these proteins' higher-level structure and function. The most productive way to indirectly exploit these databases has been to start with the small number of proteins that are fully-characterised and to assume that other "similar" proteins will have a related structure and function. Proteins with very similar amino acid sequence are "no-brainers", but the real test, which our group largely focuses on, is to detect the "essential" similarity in proteins whose non-critical sections have experienced random rearrangements during evolution. In such cases functionally similar proteins may have less than 25% sequence overlap.

More @ http://www.ncbs.res.in/sowdhamini/groups_sowdhamini.htm

MimicrEE2: Genome-wide forward simulations of Evolve and Resequencing studies

Jit — Fri, 28 Sep 2018 09:21:14 -0500

MimicrEE2, a multi-threaded Java program for genome-wide forward simulations of evolving populations. MimicrEE2 enables the convenient usage of available genomic resources, supports biological particulars of model organism frequently used in E&R studies and offers a wide range of different adaptive models (selective sweeps, polygenic adaptation, epistasis). MimicrEE2 runs on any computer with Java installed. It is distributed under the GPLv3 license at https://sourceforge.net/projects/mimicree2/.

Address of the bookmark: https://sourceforge.net/projects/mimicree2/

ALF--a simulation framework for genome evolution.

Jit — Tue, 22 Oct 2019 22:05:58 -0500

Artificial Life Framework (ALF) simulates a root genome into a number of related genomes. Result files include the resulting gene sequences, true tree and true MSAs. A description of ALF can be found in the following article:

Daniel A Dalquen, Maria Anisimova, Gaston H Gonnet, Christophe Dessimoz: ALF - A Simulation Framework for Genome Evolution. Mol Biol Evol, 29(4):1115-1123, April 2012.
http://mbe.oxfordjournals.org/content/29/4/1115

Address of the bookmark: http://alfsim.org/#index

Lecturer in Evolutionary Biology (Bioinformatics) at DEPARTMENT of ZOOLOGY | TE TARI MĀTAI KARAREHE DIVISION of SCIENCES | TE ROHE A AHIKAROA

Tue, 23 Feb 2021 02:05:15 -0600

DEPARTMENT of ZOOLOGY | TE TARI MĀTAI KARAREHE
DIVISION of SCIENCES | TE ROHE A AHIKAROA

Applications are invited for the position of Lecturer in Evolutionary Biology (Bioinformatics).

We are seeking a person with a relevant doctorate, and demonstrated potential to develop as an outstanding researcher and teacher in evolutionary bioinformatics in the Department of Zoology. The position affords an exciting opportunity for an emerging scholar to research and teach in a vibrant and diverse Department. The successful candidate will develop a transformative and collaborative research program, supporting the university's commitment to excellence in research.

Your skills and experience

A PhD with a background in analysis of high-throughput sequencing data and evolutionary biology.
Knowledge of and familiarity with a range of bioinformatics skills, concepts, and practices as they relate to the biology of animals, including genomic, transcriptomic and metabarcoding data analyses.
A strong interest, and experience, in research and teaching of bioinformatics and evolutionary genomics.
An ability to contribute to teaching and learning environments that support engagement of students and staff with bioinformatics and genomics.
Be committed to and or have established connections or track record of working with national and local bioinformaticians.
Be committed to being a productive collaborator with a track record of working collegially.
Further details

This is a confirmation-path (tenure track) position at the level of Lecturer. The successful candidate is expected to take up duties by 1 July 2021.

To see a full job description and to apply online go to: https://otago.taleo.net/careersection/2/jobdetail.ftl?job=2100342

Chromosome breakpoint - a breakup to remember

BioStar — Tue, 07 Mar 2023 13:31:54 -0600

Chromosome breakpoint refers to the physical location where a chromosome is broken and rearranged. Chromosome breakage can occur spontaneously or be induced by environmental factors such as radiation, chemicals, or viruses. The rearrangement of genetic material resulting from a chromosome breakpoint can have important consequences, including the development of genetic diseases, chromosomal abnormalities, or cancer.

Chromosome breakpoints can occur in two ways: interstitial or terminal. Interstitial breakpoints occur within the chromosome, while terminal breakpoints occur at the end of the chromosome. Terminal breakpoints can lead to the loss of genetic material, whereas interstitial breakpoints can result in the duplication or deletion of genetic material.

Chromosome breakpoints can be detected using a variety of techniques, including cytogenetic analysis, fluorescence in situ hybridization (FISH), and molecular methods such as polymerase chain reaction (PCR) and next-generation sequencing (NGS). These techniques can also help identify the exact location of the breakpoint and the nature of the rearrangement, such as translocations, inversions, deletions, or duplications.

Translocations are one of the most common types of chromosome rearrangements caused by breakpoints. In a translocation, genetic material is exchanged between two different chromosomes, resulting in a balanced or unbalanced distribution of genetic material. Unbalanced translocations can cause genetic diseases or developmental abnormalities, while balanced translocations can be inherited without any apparent phenotypic effects.

Inversions occur when a chromosome segment is inverted, resulting in a change in the order of genetic material. Inversions can be pericentric, involving the centromere, or paracentric, not involving the centromere. Inversions can cause genetic diseases or phenotypic effects if they disrupt the function of essential genes or regulatory elements.

Deletions and duplications are caused by interstitial breakpoints that result in the loss or gain of genetic material. Deletions can cause genetic diseases or developmental abnormalities if they involve essential genes or regulatory elements. Duplications can also have phenotypic effects, depending on the location and size of the duplicated segment.

Chromosome breakpoints can also be involved in the formation of complex chromosomal rearrangements, such as ring chromosomes or dicentric chromosomes. These complex rearrangements can have important clinical implications, as they can cause genetic diseases or cancer.

In conclusion, chromosome breakpoints are important genetic events that can lead to the rearrangement of genetic material and have important clinical implications. The detection and characterization of chromosome breakpoints using cytogenetic, molecular, and genomic methods are essential for the diagnosis, prognosis, and treatment of genetic diseases and cancer. Further research is needed to understand the molecular mechanisms underlying chromosome breakage and to develop new therapies targeting these events.

Fiona Brinkman Laboratory

Sun, 14 Jul 2013 12:46:31 -0500

Infectious disease control needs to be made more “sustainable”. We need to reduce selective pressure on pathogens to evolve antibiotic resistance. We need to control infectious disease outbreaks and associated immune disorders with a better understanding of the genetic, environmental and social factors that impact disease spread and severity.

Research Area

Investigating the role in disease of both the microbe and its host (i.e immune system failure), using genomics and systems biology-based approaches
Using genomics and network analysis to characterize disease outbreaks and their environmental/social/genetic causes, and
Identifying new anti-infective and immune modulating therapies/biomarkers.

Link @ http://www.brinkman.mbb.sfu.ca/

BioProgramming

Jitendra Narayan — Sun, 14 Jul 2013 16:29:53 -0500

The completion of the first human genome drafts was just a start of the modern DNA sequencing era which resulted in further invention, improved development toward new advanced strategies of high-throughput DNA sequencing, so called the “high-throughput next generation sequencing” (HT-NGS). The decreasing genome sequencing cost and desire to explore and understand biological machanism at genomic level, speed up the genomic sequencing projects. In the fast growing HT-NGS technologies, the main challenge is to cope with the analysis of vast production of sequencing database through advanced bioinformatics tools. In oder to develope sotware/tools bioinformatician/ biological programmers need to expertise in any one one the programming language. However, sometime one language are not enough to handle all sort of biological needs, which compel us to learn new biologically suitable language to handle ever growing genome or protein sequences.

The next step after reading genetic code is writing a script to analyse and explore the hidden information. This tutorial is aimed to introduce you new biological programming languages with their packages/libraries, and assist in your scripting work.

Navigate the sub-section of this page [ see right hand side of the page for it ]

ISCB-Asia 2013 Translational Bioinformatics Conference

Thu, 08 Aug 2013 06:31:32 -0500

ISCB-Asia 2013
Translational Bioinformatics Conference
Seoul, Korea
October 2 - 4, 2013

For more information visit: http://www.snubi.org/TBC2013/

2013 NextGen Genomics & Bioinformatics Technologies (NGBT) Conference, New Delhi, INDIA

Thu, 08 Aug 2013 16:21:16 -0500

2013 NextGen Genomics & Bioinformatics Technologies (NGBT) Conference

SciGenom Research Foundation (SGRF) and Institute of Genomics and Integrative Biology (IGIB) are pleased to host the Next-Generation Sequencing and Bioinformatics for Genomics & Healthcare conference.

In the ten years since the first human reference genome was completed for US$3 billion the sequencing technologies have radically changed leading to great reduction in sequencing cost. Today a human genome can be sequenced for under US$ 5000 in less than two weeks. It is expected that by the end of 2015 the cost of sequencing a human genome will drop to below thousand dollars. The next generation sequencing technologies over the past five years have enabled a large number of genomic studies that impact human health and disease. Also, this has made possible the growth of microbial, animal and plant genomics studies. While the data production has increased at a rapid pace challenges remain in analyzing and understanding the data. The conference will cover the next generation sequencing (NGS) technologies, bioinformatics for NGS and applications of NGS in many areas including personalized medicine.

For more info : http://www.scigenomconferences.com/2013/default.php

India's own first drug - from Biocon.

Jitendra Narayan — Sun, 11 Aug 2013 16:05:39 -0500

Psoriasis is immune-mediated disease that effects the skin. the Disease on an average affects about 10-20 million Indians and it attacks the immune system of human beings. In generally occurs, when the immune system mistakes a normal skin cell for a pathogen, and sends out faulty signals that cause overproduction of new skin cells. More at >>

Biocon, India's largest publicly-held biotechnology firm, launched its second novel 'lab-to-market' molecule, Alzumab, to treat chronic plaque psoriasis at a cost 50 per cent lower than the existing one.

Biocon is bringing Alzumab (a biologic) in the form of a vial after working on it for nearly a decade. The work had initially started in a joint effort with the Center of Molecular Immunology, Havana, but Biocon took control of the programme soon after and also bought out its partner a few years ago. Biocon tell to the media that genotypic played a critical role in functional studies and clinical trial Genomics.

The Biocon drug, at around ₹ 7,500 a vial, will cost half as much as the currently available drugs - from Pfizer and J&J - to treat psoriasis, a skin disease that causes rough red areas where the skin comes off in small pieces. A patient is usually prescribed to consume more than 40 vials in a 24-week course.